TICKERNERD
Menu
ANIXANIXHealthcare · Biotechnology

ANIX Stock Forecast: Anixa Biosciences, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$2.91
−1.36% on the day

The 4 Wall Street analysts covering Anixa Biosciences, Inc. hold a median 12-month price target of $9.5 — +226.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 8 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$105.0M
Ticker Nerd rank
72 / 100
Median analyst target
$9.50
Analysts covering
4
Revenue$0.0
Operating income−$2.7M
Net income−$2.6M
Free cash flow−$1.8M
Quarterly, 8 quarters to 31 July 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.1%
1M
+0.3%
YTD
−6.7%
1Y
−34.5%
From 52W high
−44.3%
From 52W low
+23.8%
$2.35
$5.22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ANIX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Anixa Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
80
Size
75
Volatility
71
Revisions
67
Accruals
65
Issuance
54
Momentum
46
Quality
44
Growth
43

Value (80): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Growth (43): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ANIX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ANIX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26ANIXHigh $14.00Median $9.50Low $6.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $6.00Median $9.50High $14.00

The green dot is the last close — the median target sits +226.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 Sept 2026HC Wainwright & Co.MaintainsBuy$7.00 → $6.00
30 June 2026D. Boral CapitalAssumesBuy$10
8 Apr 2026D. Boral CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalMaintainsBuy—
4 Feb 2026D. Boral CapitalMaintainsBuy—
12 Dec 2025D. Boral CapitalMaintainsBuy—
7 Oct 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
11 Sept 2025HC Wainwright & Co.ReiteratesBuy—
9 Sept 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025D. Boral CapitalMaintainsBuy—
5 Aug 2025D. Boral CapitalMaintainsBuy—
10 June 2025D. Boral CapitalMaintainsBuy—
29 May 2025D. Boral CapitalMaintainsBuy—
10 Apr 2025D. Boral CapitalMaintainsBuy—
26 Mar 2025D. Boral CapitalMaintainsBuy—
25 Mar 2025HC Wainwright & Co.ReiteratesBuy—
21 Mar 2025Maxim GroupInitiatesBuy—
18 Feb 2025HC Wainwright & Co.ReiteratesBuy—
22 Jan 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANIX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ANIX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Anixa Biosciences, Inc. returned −34.5% against +16.2% for the S&P 500, dividends included.

ANIX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26ANIXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ANIX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Anixa Biosciences, Inc. (ANIX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−8.9×

Cheaper than 93% of US stocks

Price / sales
—
Price / book
7.2×

Cheaper than 13% of US stocks

EV / EBITDA
−7.7×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−73.2%

Higher than 17% of US stocks

Return on assets
−41.9%

Higher than 10% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Anixa Biosciences, Inc. (ANIX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Anixa Biosciences, Inc. has a market value of $105.0M and an enterprise value of $90.0M.

  • Revenue in the twelve months to 31 July 2026: $0.0.

  • Net income over the same four quarters: −$10.5M.

  • Free cash flow in the twelve months to 31 July 2026: −$7.4M.

  • Shares outstanding: 34.6M.

  • Trailing P/E: −8.9×; forward P/E: −9.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Anixa Biosciences, Inc. employs 4 people.

Statement figures: company filings via Twelve Data, four quarters to 31 July 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

ANIX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ANIXAnixa Biosciences, Inc.$105.0M
72
CRBPCorbus Pharmaceuticals Holdings, Inc.$97.6M
19
CNXUConexeu Sciences, Inc.$97.3M
1
BMEABiomea Fusion, Inc.$96.9M
55
PYPDPolyPid Ltd.$99.5M
56
PLYXPolaryx Therapeutics, Inc.$99.7M
16
OKUROnKure Therapeutics, Inc.$92.9M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Anixa Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ANIX news & analysis

Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

PRNewsWire · 5 Oct 2026positive

Anixa Biosciences announced that the first patient in the current dose cohort of its Phase 1, dose-escalating clinical trial evaluating its FSHR-targeted CAR-T therapy for recurrent ovarian cancer exhibited stable disease 90 days after treatment. The company also noted that multiple patients have survived more than one year, including one beyond two years, with no dose-limiting toxicities observed to date.

Why it matters — For Anixa watchers, this update offers early clinical evidence that the company's CAR-T therapy may provide durable disease stabilization in recurrent ovarian cancer patients, a meaningful milestone in its ongoing Phase 1 trial.

Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

PRNewsWire · 1 Oct 2026positive

Anixa Biosciences announced that the second patient has been treated in the fifth cohort of its ongoing Phase 1, dose-escalating clinical trial evaluating its FSHR-targeted CAR-T therapy for recurrent ovarian cancer. Multiple patients have survived more than one year, including one beyond two years, with no dose-limiting toxicities observed to date.

Why it matters — ANIX watchers would care because the trial's reported long-term survival and safety data support continued progress in the company's ovarian cancer CAR-T program.

Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

PRNewsWire · 21 Sept 2026positive

Anixa Biosciences announced that IP Australia issued Patent Number 2020221280 for its breast cancer vaccine technology, which is exclusively licensed from Cleveland Clinic. The composition-of-matter patent protects the vaccine in Australia through 2040, expanding the company's global intellectual property estate.

Why it matters — The Australian patent extends Anixa's exclusive international IP protection for its breast cancer vaccine into a market with rising breast cancer incidence, strengthening its global patent position through 2040.

Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

PRNewsWire · 16 Sept 2026positive

Anixa Biosciences announced the appointment of Dr. Carmen Guerra, a physician from the University of Pennsylvania, to its Cancer Business Advisory Board. The company, which focuses on cancer treatment and prevention, made the announcement via a PRNewswire release on September 16, 2026.

Why it matters — Adding a respected academic physician like Dr. Guerra to its advisory board may strengthen the company's expertise and credibility in the cancer field, which ANIX watchers would view as a constructive development.

Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

PRNewsWire · 9 Sept 2026neutral

Anixa Biosciences announced that an interview featuring Chairman and CEO Dr. Amit Kumar and breast cancer vaccine clinical trial patient Sherie Steinberg will air on the RedChip Small Stocks, Big Money™ show on Bloomberg TV on Saturday, September 12 at 7:00 PM ET.

Why it matters — The interview provides public visibility for Anixa's breast cancer vaccine program and its clinical trial progress to a broader television audience.

FAQ

Frequently asked questions about ANIX stock

What is the ANIX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Anixa Biosciences, Inc. have a median 12-month price target of $9.5, with estimates ranging from $6 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ANIX stock a buy right now?

Of the 4 analysts covering Anixa Biosciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Anixa Biosciences, Inc. 72 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ANIX?

As at 8 Oct 2026, Anixa Biosciences, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (80 of 100).

Will ANIX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +226.5% from the last close, and Ticker Nerd's factor model ranks Anixa Biosciences, Inc. 72 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ANIX stock forecast for 2030?

No analyst covering Anixa Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANIX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $14 over the next 12 months.

How has ANIX stock performed over the past year?

Anixa Biosciences, Inc. returned -34.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Anixa Biosciences, Inc. do?

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer.

What is the latest news on ANIX?

The most recent item we track (PRNewsWire, 5 Oct 2026): "Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial". Anixa Biosciences announced that the first patient in the current dose cohort of its Phase 1, dose-escalating clinical trial evaluating its FSHR-targeted CAR-T therapy for recurrent ovarian cancer exhibited stable disease 90 days after treatment. The company also noted that multiple patients have survived more than one year, including one beyond two years, with no dose-limiting toxicities observed to date.

Company

About Anixa Biosciences, Inc.

Anixa Biosciences, Inc. is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. The company develops cancer vaccines and cell-based immunotherapies, including programs centered on breast cancer, ovarian cancer, and other hard-to-treat solid tumors. Its work includes vaccine platforms designed to stimulate immune responses against cancer-related targets and a CAR-T-based therapeutic approach aimed at oncology applications. Anixa Biosciences also explores complementary diagnostics and related research programs that support early detection and cancer management. Headquartered in San Jose, California, Anixa Biosciences serves the biotechnology and oncology markets through a pipeline of current products and development programs that address unmet needs in cancer care.

CEO Dr. Amit Kumar Ph.D. · 4 employees · United States · https://www.anixa.com